Blood doping and its cardiovascular consequences;Le dopage sanguin et ses consequences cardiovasculaires

Presse Medicale

Volumn 31, Issue 40, 2002, Pages 1904-1908

  Gauthier, Jean ^a,b  

^a Club des Cardiologues du Sport   (France)

^b Chemin de la Croix de Cajeneuve   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; EFAPROXIRAL; ERYTHROPOIETIN; FLUOROCARBON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

BLOOD TRANSFUSION; CLINICAL PRACTICE; DOPING; HEART OUTPUT; HUMAN; HYPERVISCOSITY SYNDROME; INCIDENCE; OXYGEN SUPPLY; PHYSICIAN; PRESCRIPTION; REVIEW; RISK FACTOR; THROMBOSIS;

ANILINE COMPOUNDS; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASES; COLONY-STIMULATING FACTORS; DOPING IN SPORTS; FLUOROCARBONS; HUMANS; PROPIONIC ACIDS; RISK FACTORS;

EID: 0037153757     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Remy B, Deby-Dupont G. Apports et perspectives des dérivés de l'hémoglobine. J Suisse Med 1997; 127: 1088-96.
2. Everse J, Hsia N. The toxicities of native and modified hemoglobins. Free Radical Biol Med 1997; 22: 1075-99.
3. Kim SA, Villa VO, Hess JR. Denatured hemoglobin increases human blood mononuclear cell procoagulant effect. Artificial Cells, Blood Substitutes and Immobilization Biotechnolog. 1994; 22: 625-31
4. Bleeker WK, de Groot EM. Measurement of interleukin production by monocytes for in vitro safety testing of hemoglobin solutions. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 1994; 22: 835-40.
5. Carlini RG, Dusso AS. Recombinant human erythropoietin increases endothelin-I release by endothelial cells. Kidney Int 1993; 43: 1010-14
6. Ismael N, Ikizler TA. Erythropoietin-induced hypertension. Lebanese Med J 1997; 45: 25-30.
7. Schiffl H, Lang SM. Hypertension induced by Recombinant Human Erythropoietin (rHU EPO) can be prevented by indomethacin. Eur J Med Res 1997; 2: 97-100.
8. Houmes RJ, Verbrugge SJ. Hemodynamic effects of partial liquid ventilation with perfluorocarbon in acute lung injury. Intensive Care Med 1995; 2: 966-72.
9. Patel S, Mehra A. Modeling of oxygen transport in perfluorocarbon emulsion mixtures: Part II: Tissue oxygenation. ASIAO J. 1998; 44: 157-65.
10. Allos Therapeutics Reports Positive Results from Phase II Study of RSR 13 for Non-Small Cell Lung Cancer at ASCO. PR Newswire; SanFrancisco: May 2001
11. Allos Therapeutics Initiates Clinical Study of RSR 13 combined with chemotherapy for recurrent brain cancer. PR Newswire; Denver: Jan 2001